Can-Fite BioPharma announced that the Company’s Director of Business Development Dr. Sari Fishman will conduct virtually one-on-one meetings with Japanese companies specializing in the development of Orphan Drugs, at the BioJapan Conference held from October 11-13, 2023, in Yokohama, Japan. Can-Fite signed recently an agreement with Fondazione Telethon for the co-development of Piclidenoson for the treatment of Lowe syndrome based on breakthrough findings of Dr. Antonella De Matteis that the Can-Fite drug Piclidenoson is efficacious in pre-clincial studies in treating Lowe Syndrome. FDA & EMA approvals for rare genetic diseases are faster and require clinical studies with smaller number of patients. Additional meetings with Japanese companies who are interested in the Oncology and Dermatology Can-Fite’s indications will take place as well. “The Lowe Syndrome is Can-Fite’s first rare genetic disease indication and I am happy that it raises high interest of Japanese companies who are experts in the orphan drug arena. The conference provides us with the opportunity to present our other developments to lead Japanese pharmaceutical companies,” stated Dr. Sari Fishman, Director of Business Development at Can-Fite.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CANF:
- Can-Fite : Namodenoson inhibits pancreatic cancer growth in pre-clinical studies
- Can-Fite BioPharma files $100M mixed securities shelf
- Can-Fite BioPharma reports 1H revenue $390K vs. $410K for 1H last year
- CANF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Can-Fite BioPharma plans to develop Piclidenoson for treatment of Lowe Syndrome